By Dennis Douda, Mayo Clinic.org, Special to SouthFloridaReporter.com – June 17, 2015 – A Food and Drug Administration (FDA) advisory panel has recommended approval of the first drug in a new class of cholesterol-lowering medications, called PCSK9 inhibitors. PCSK9 is a protein that interferes with the liver’s ability to reduce levels of LDL, often called the bad cholesterol. A similar drug made by another company will be considered by the panel today. “The thing that’s different about [these medications] is 
that they actually enhance your own body’s ability to clear cholesterol,” saysStephen Kopecky, M.D., with Mayo Clinic‘s division ofcardiovascular diseases and the immediate past president of the American Society for Preventive Cardiology (ASPC).
Mayo Clinic participated in some of the research to evaluate the medications. “Of the three that are coming along, we’ve studied two of them here, giving them to patients in research studies and looked at their benefits and side effects; their good effects and bad effects. We’ve found them to be very, very effective,” Dr. Kopecky says.
Play the video to hear more of Dr. Kopecky’s comments about how the drugs work and why they could be lifesavers for some patients with high cholesterol.
Disclaimer
The information contained in South Florida Reporter is for general information purposes only.
The South Florida Reporter assumes no responsibility for errors or omissions in the contents of the Service.
In no event shall the South Florida Reporter be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service. The Company reserves the right to make additions, deletions, or modifications to the contents of the Service at any time without prior notice.
The Company does not warrant that the Service is free of viruses or other harmful components
